Phase 2 Study Update of ENMD-2076 for Recurrent, Platinum-Resistant Ovarian Cancer

EntreMed, Inc. announced results from a Phase 2 trial of ENMD-2076 in recurrent, platinum-resistant ovarian cancer.

The trial was an open-label, single-arm Phase 2 study of single agent ENMD-2076 taken daily orally. A total of 64 patients enrolled.

The progression free survival rate at 6 months was 22%, with a median time to progression of 3.6 months while median number of prior chemotherapy regimens was 2 months. 

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis, and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers.

For more information call (240) 864-2600 or visit www.entremed.com.